授权
大流行性流感
佐剂
大流行
2019年冠状病毒病(COVID-19)
医学
业务
风险分析(工程)
病毒学
计算机科学
免疫学
计算机安全
传染病(医学专业)
疾病
病理
作者
Xiangchuan He,Tianxiang Zhang,Shitong Huan,Yue Yang
出处
期刊:Vaccines
[MDPI AG]
日期:2023-10-09
卷期号:11 (10): 1573-1573
标识
DOI:10.3390/vaccines11101573
摘要
Influenza vaccines faced significant challenges in achieving sufficient protective efficacy and production efficiency in the past. In recent decades, novel influenza vaccines, characterized by efficient and scalable production, advanced platforms, and new adjuvant technologies, have overcome some of these weaknesses and have been widely licensed. Furthermore, researchers are actively pursuing the development of next-generation and universal influenza vaccines to provide comprehensive protection against potential pandemic subtypes or strains. However, new challenges have emerged as these novel vaccines undergo evaluation and authorization. In this review, we primarily outline the critical challenges and advancements in research and development (R&D) and highlight the improvements in regulatory responses for influenza vaccines.
科研通智能强力驱动
Strongly Powered by AbleSci AI